A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies.

Clara AlconAlbert Manzano-MuñozJoan Montero

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

CDK9-specific inhibition with AZD4573 impairs cancer-promoting gene expression such as MCL-1 and has been proven effective in hematologic malignancies preclinical models. This new clinical candidate should be further explored in the clinic not only as a monotherapy but also in combination with BH3 mimetics to prevent treatment resistance.See related article by Cidado et al., p. 922.

Keyphrases

gene expression
cell cycle
combination therapy
papillary thyroid
dna methylation
primary care
squamous cell
randomized controlled trial
open label
clinical trial
squamous cell carcinoma
stem cells
cell therapy
mesenchymal stem cells
bone marrow
smoking cessation
drug induced